Perspective Therapeutics, Inc. (NYSE: CATX) is down 13% at $11.53 at last check Friday. The downtrend comes as initial results from its study of [212Pb]VMT01 are set to be presented to the International Congress of the Society for Melanoma Research. VMT01 is a MC1R-targeted radiopharmaceutical therapy (RPT) that can be radiolabeled with either 203Pb for patient selection and dosimetry assessments or 212Pb for alpha particle therapy. In preclinical experiments [212Pb] VMT01 demonstrated efficacy via direct cell killing at high radiation doses and through immunostimulatory low-dose induction of …